{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T07:25:30Z","timestamp":1791962730393,"version":"4.3.4"},"reference-count":44,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Scientific Research Projects Unit of Altinbas University","award":["PB2022-TIP-5"],"award-info":[{"award-number":["PB2022-TIP-5"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Chronic myeloid leukemia (CML) is a blood disorder caused by a genetic alteration that creates the BCR-ABL fusion gene, leading to continuous activation of cell growth signals and uncontrolled proliferation of the blood cells. Imatinib (IMA) resistance remains a major obstacle in CML treatment. Integrins, particularly integrin \u03b12 (ITGA2), have been associated with cancer progression and drug resistance. In the current study, we investigated the role of ITGA2 in IMA resistance using IMA-sensitive K562 (K562S) and IMA-resistant K562 (K562R) cells. Our findings showed that ITGA2 is overexpressed in K562R cells and ITGA2 inhibitor E7820 (2.5 \u00b5M) treatment significantly decreased cell viability and induced apoptosis in both sensitive and resistant cells. Combination treatment with E7820 and imatinib enhanced pro-apoptotic gene expression (BAX, BIM) and decreased anti-apoptotic BCL2 levels in imatinib-resistant K562R cells. Flow cytometry confirmed ITGA2 inhibition at the protein level, and rhodamine assays revealed reduced MDR1 activity in treated cells. These results demonstrate that targeting ITGA2 may overcome imatinib resistance and offer a novel therapeutic strategy for CML.<\/jats:p>","DOI":"10.3390\/biom15091245","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T15:03:14Z","timestamp":1756393394000},"page":"1245","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting Integrin \u03b12 to Overcome Imatinib Resistance in Chronic Myeloid Leukemia Cells"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4683-074X","authenticated-orcid":false,"given":"Yalda","family":"Hekmatshoar","sequence":"first","affiliation":[{"name":"Department of Medical Biology, School of Medicine, Altinbas University, 34147 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulin","family":"Ozkan","sequence":"additional","affiliation":[{"name":"Department of Medical Biology, School of Medicine, Ankara University, 06230 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arzu Zeynep","family":"Karabay","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Pharmacy, Ankara University, 06560 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sureyya","family":"Bozkurt","sequence":"additional","affiliation":[{"name":"Department of Medical Biology, School of Medicine, Istinye University, 34396 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aynur Karadag","family":"Gurel","sequence":"additional","affiliation":[{"name":"Department of Medical Biology, Gulhane Faculty of Medicine, Health Sciences University, 06018 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem Kurnaz","family":"Gomleksiz","sequence":"additional","affiliation":[{"name":"Department of Medical Biology, School of Medicine, Altinbas University, 34147 Istanbul, Turkey"},{"name":"Central Research Laboratory, Altinbas University, 34147 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunc","family":"Fisgin","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology-Oncology and Transplantation Unit, School of Medicine, Altinbas University, 34147 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuman","family":"Sunguroglu","sequence":"additional","affiliation":[{"name":"Department of Medical Biology, School of Medicine, Ankara University, 06230 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3892\/or.2022.8355","article-title":"Genome-wide expression and methylation analyses reveal aberrant cell adhesion signaling in tyrosine kinase inhibitor-resistant CML cells","volume":"48","author":"Kaehler","year":"2022","journal-title":"Oncol. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Amarante-Mendes, G.P., Rana, A., Datoguia, T.S., Hamerschlak, N., and Brumatti, G. (2022). BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14010215"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"24326","DOI":"10.1073\/pnas.2009078117","article-title":"Kindlin-3 loss curbs chronic myeloid leukemia in mice by mobilizing leukemic stem cells from protective bone marrow niches","volume":"117","author":"Krenn","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.14715\/cmb\/2018.64.6.5","article-title":"Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms","volume":"64","author":"Hekmatshoar","year":"2018","journal-title":"Cell. Mol. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.advms.2023.06.002","article-title":"Phenotypic and functional characterization of subpopulation of Imatinib resistant chronic myeloid leukemia cell line","volume":"68","author":"Hekmatshoar","year":"2023","journal-title":"Adv. Med. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Shishido, S., Bonig, H., and Kim, Y.M. (2014). Role of integrin alpha4 in drug resistance of leukemia. Front. Oncol., 4.","DOI":"10.3389\/fonc.2014.00099"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Scharff, B., Modvig, S., Marquart, H.V., and Christensen, C. (2020). Integrin-Mediated Adhesion and Chemoresistance of Acute Lymphoblastic Leukemia Cells Residing in the Bone Marrow or the Central Nervous System. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00775"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nrd3266","article-title":"Integrins as therapeutic targets: Lessons and opportunities","volume":"9","author":"Cox","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.gendis.2018.12.003","article-title":"Regulation and functions of integrin alpha2 in cell adhesion and disease","volume":"6","author":"Liu","year":"2019","journal-title":"Genes. Dis."},{"key":"ref_11","first-page":"79","article-title":"The integrin alpha 4 beta 1 (VLA-4) as a therapeutic target","volume":"189","author":"Elices","year":"1995","journal-title":"Ciba Found. Symp."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1038\/leu.2009.175","article-title":"Contribution of bone microenvironment to leukemogenesis and leukemia progression","volume":"23","author":"Ayala","year":"2009","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1111\/j.1538-7836.2005.01273.x","article-title":"Platelet glycoprotein I(b)alpha and integrin alpha2 beta1 polymorphisms: Gene frequencies and linkage disequilibrium in a population diversity panel","volume":"3","author":"Jugessur","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"ref_14","first-page":"113","article-title":"Widespread histologic distribution of the alpha 2 beta 1 integrin cell-surface collagen receptor","volume":"137","author":"Zutter","year":"1990","journal-title":"Am. J. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1182\/blood.V86.8.3006.3006","article-title":"Regulation of alpha 2 integrin gene expression in cells with megakaryocytic features: A common theme of three necessary elements","volume":"86","author":"Zutter","year":"1995","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.cellsig.2014.05.016","article-title":"Alpha2beta1 integrin promotes T cell survival and migration through the concomitant activation of ERK\/Mcl-1 and p38 MAPK pathways","volume":"26","author":"Naci","year":"2014","journal-title":"Cell. Signal."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"9584","DOI":"10.1002\/jcp.26866","article-title":"Methylation-independent ITGA2 overexpression is associated with poor prognosis in de novo acute myeloid leukemia","volume":"233","author":"Lian","year":"2018","journal-title":"J. Cell Physiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7320","DOI":"10.1158\/0008-5472.CAN-09-0315","article-title":"Integrin alpha2 mediates selective metastasis to the liver","volume":"69","author":"Yoshimura","year":"2009","journal-title":"Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.tips.2012.04.002","article-title":"Integrins as therapeutic targets","volume":"33","author":"Goodman","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kobayashi, N., Oda, T., Takizawa, M., Ishizaki, T., Tsukamoto, N., Yokohama, A., Takei, H., Saitoh, T., Shimizu, H., and Honma, K. (2020). Integrin alpha7 and Extracellular Matrix Laminin 211 Interaction Promotes Proliferation of Acute Myeloid Leukemia Cells and Is Associated with Granulocytic Sarcoma. Cancers, 12.","DOI":"10.3390\/cancers12020363"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.bbrc.2003.10.054","article-title":"Involvement of p53 in alpha4beta1 integrin-mediated resistance of B-CLL cells to fludarabine","volume":"311","author":"Casanova","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1182\/blood-2012-01-406272","article-title":"Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy","volume":"121","author":"Hsieh","year":"2013","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1038\/leu.2016.88","article-title":"CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia","volume":"30","author":"Bulian","year":"2016","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/nm909","article-title":"Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia","volume":"9","author":"Matsunaga","year":"2003","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood.V93.5.1658","article-title":"Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines","volume":"93","author":"Damiano","year":"1999","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Liu, T., Gu, Y., Zhang, Y., and Li, Y. (2024). Integrin alpha2 in the microenvironment and the tumor compartment of digestive (gastrointestinal) cancers: Emerging regulators and therapeutic opportunities. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1439709"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13046-022-02286-5","article-title":"Overexpressed integrin alpha 2 inhibits the activation of the transforming growth factor beta pathway in pancreatic cancer via the TFCP2-SMAD2 axis","volume":"41","author":"Cai","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_28","first-page":"809","article-title":"Significance of integrin alpha2\/beta1 in peritoneal dissemination of a human gastric cancer xenograft model","volume":"18","author":"Kawamura","year":"2001","journal-title":"Int. J. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/neuonc\/noac237","article-title":"Targeting integrin alpha2 as potential strategy for radiochemosensitization of glioblastoma","volume":"25","author":"Korovina","year":"2023","journal-title":"Neuro Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Rattanasinchai, C., Navasumrit, P., and Ruchirawat, M. (2022). Elevated ITGA2 expression promotes collagen type I-induced clonogenic growth of intrahepatic cholangiocarcinoma. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-26747-1"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Wang, Q., Cao, T., Guo, K., Zhou, Y., Liu, H., Pan, Y., Hou, Q., Nie, Y., Fan, D., and Lu, Y. (2020). Regulation of Integrin Subunit Alpha 2 by miR-135b-5p Modulates Chemoresistance in Gastric Cancer. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00308"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1158\/1078-0432.CCR-16-2180","article-title":"HMGA2-FOXL2 Axis Regulates Metastases and Epithelial-to-Mesenchymal Transition of Chemoresistant Gastric Cancer","volume":"23","author":"Dong","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s10495-019-01573-5","article-title":"Integrin-EGFR interaction regulates anoikis resistance in colon cancer cells","volume":"24","author":"Guha","year":"2019","journal-title":"Apoptosis"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"17065","DOI":"10.1074\/jbc.M112.349365","article-title":"alpha2beta1 integrin promotes chemoresistance against doxorubicin in cancer cells through extracellular signal-regulated kinase (ERK)","volume":"287","author":"Naci","year":"2012","journal-title":"J Biol Chem"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Naci, D., Berrazouane, S., Barabe, F., and Aoudjit, F. (2019). Cell adhesion to collagen promotes leukemia resistance to doxorubicin by reducing DNA damage through the inhibition of Rac1 activation. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-55934-w"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/cas.12450","article-title":"Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models","volume":"105","author":"Ito","year":"2014","journal-title":"Cancer Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/jjco\/hyac148","article-title":"Integrin alpha 2 is associated with tumor progression and postoperative recurrence in non-small cell lung cancer","volume":"53","author":"Matsumoto","year":"2023","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s43188-022-00127-3","article-title":"Role of integrin alpha2 in methotrexate-induced epithelial-mesenchymal transition in alveolar epithelial A549 cells","volume":"38","author":"Kawami","year":"2022","journal-title":"Toxicol. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nchembio.2363","article-title":"Selective degradation of splicing factor CAPERalpha by anticancer sulfonamides","volume":"13","author":"Uehara","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4149\/neo_2020_190604N486","article-title":"Suppression of \u03b1v\u03b26 downregulates P-glycoprotein and sensitizes multidrug-resistant breast cancer cells to anticancer drugs","volume":"67","author":"Zhang","year":"2020","journal-title":"Neoplasma"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"101460","DOI":"10.1016\/j.tranon.2022.101460","article-title":"Silencing PLOD2 attenuates cancer stem cell-like characteristics and cisplatin-resistant through Integrin \u03b21 in laryngeal cancer","volume":"22","author":"Song","year":"2022","journal-title":"Transl. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1124\/mol.112.082339","article-title":"Upregulation of drug transporter expression by osteopontin in prostate cancer cells","volume":"83","author":"Hsieh","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1038\/s41375-023-02050-4","article-title":"E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: A phase II clinical trial","volume":"37","author":"Bewersdorf","year":"2023","journal-title":"Leukemia"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/9\/1245\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:34:32Z","timestamp":1760034872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/9\/1245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":44,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["biom15091245"],"URL":"https:\/\/doi.org\/10.3390\/biom15091245","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]}}}